The next generation of GLP-1s came along as Novo Nordisk released semaglutide, which was approved for type 2 diabetes in 2017 (as Ozempic) and for obesity in 2021 (as Wegovy)
It generally manifests as a sensory neuropathy, which can be irreversible
If that proves to be the case, doctors might someday optimize patients GLP-1 regimens for long-term cardiovascular benefits, not just for diabetes management and weight loss, researchers said in a report published online ahead of peer review
For nauseathe most common GLP-1 side effectnote whether it occurs primarily after injections, with meals, or throughout the day
Your prescriber can help you distinguish between normal adjustment and genuine intolerance
This extra effort puts significant strain on the bodys metabolic system